

James D. Neaton

April 2007

CURRICULUM VITAE

James D. Neaton

Name: James Dennis Neaton

Title: Professor, Biostatistics

Address: Coordinating Centers for Biometric Research
Division of Biostatistics
School of Public Health
University of Minnesota
2221 University Avenue SE, Suite 200
Minneapolis MN 55414



Education:

Major Field

Degree

| | | | |
|---|-----------|-------------|-------|
| Lamar University Beaumont, Texas | 1965-1968 | Mathematics | None |
| University of Minnesota School of Public Health Biometry Division | 1968-1969 | Biometry | B.A. |
| University of Minnesota | 1969-1970 | Biometry | M.S. |
| University of Minnesota | 1984 | Biometry | Ph.D. |

Honors:

B.A. Awarded with Honors
Pi Mu Epsilon
Delta Omega Honorary Public Health Society
Leonard M. Schuman Excellence in Teaching Award
Fellow, American Statistical Association

Membership in Professional Societies:

Society for Clinical Trials, President 2006-2007
Biometric Society, ENAR
American Statistical Association
American Heart Association Council on Epidemiology
International Society and Federation of Cardiology, Scientific Section on
Epidemiology and Prevention
International AIDS Society

Professional Experience:

- Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1995 - present
- Adjunct Professor of Medicine, Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 2006-present.
- Associate Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1990 - 1995
- Assistant Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1985 - 1990
- Research Fellow, Biometry Division, School of Public Health, University Minnesota, 1973 - 1985
- USPHS Officer Assigned to Biometrics Research Branch, National Heart and Lung Institute, NIH, 1970-1972.

Grant and Contract Support:

- Principal Investigator, NIAID International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), 2006 - Present.
- Co-Director, Roadmap Multidisciplinary Clinical Research Career Development Program (K12), 2005-Present.
- Principal Investigator, Coordinating Center for the SILCAAT Study sponsored by Chiron and the National Institutes of Health, 2003 - Present.
- Principal Investigator, NIAID Statistical Center and Data Management Center for Community Programs for Clinical Research on AIDS, 1990 - 2006.
- Principal Investigator, NIAID International Trial of IL-2 (ESPRIT), 1999- 2006.
- Principal Investigator, NHLBI Extended Mortality and Follow-up and Analyses of Men in the MRFIT, 2001 -2006.
- Principal Investigator, Coordinating Center, _____ Study, 1996 - 2004.
- Director, Biostatistics Core, NCI Great Lakes Center for AIDS Research, 1998- 2003.
- Principal or Co-Principal Investigator, NHLBI Multiple Risk Factor Intervention Trial (MRFIT) Coordinating Center, 1973 - 1999.
- Principal Investigator, NHLBI Mortality Surveillance of MRFIT Screenees, 1989-1999.
- Co-Principal Investigator and Director of the Coordinating Center for NHLBI Treatment of Mild Hypertension Study (TOMHS), 1985 - 1996.
- Co-Investigator of primary grant and Principal Investigator of Statistical Center for a Prospective Study of Blood Pressure and ESRD, 1991 - 1996.
- Co-Principal Investigator and Director of Data Coordinating Center for NHLBI Study of Potassium and Sodium to Control Blood Pressure in Hypertensives, 1983 - 1988.
- Co-Investigator, NEI Diabetic Retinopathy Vitrectomy Study: 1975-1980

James D. Neaton

Co-Investigator, NHLBI Granulocyte Transfusion Study, 1977-1979

Co-Principal Investigator and Director of Data Coordinating Center for Study of the Effect of Clonidine on Plasma Lipids, 1985 - 1986.

Editorial and Advisory Committees:

President, Society for Clinical Trials, 2006-2007

Advisory Board, *Clinical Trials*, 2004-present.

Chair, MRFIT Editorial Committee, 1997-present.

U.S. Public Health Service - Infectious Disease Society Joint Task Force on Prevention of Opportunistic Infection in Patients with HIV-Infection, 1994 – present.

U.S. Public Health Service - Panel on Clinical Practices for the Treatment of HIV Infection, 1999 - present.

Editor in Chief, *Controlled Clinical Trials*, 1999-2003.

Advisory Committee, Inventory and Evaluation of Clinical Research Networks (IECRN), NIH Roadmap Project, Westat, 2005-2006.

Participant, NIH Director's Clinical Research Roadmap Meeting, 2003.

Participant, NIH Director's Meeting for Investigators on Open Access, 2004.

Member, NHLBI Strategic Planning Group, 2006

Consultant, South Africa PHIDISA Project, NIH, 2003 - Present.

TrialNet External Advisory Committee, NIDDK, NIH, 2006-present

Data Monitoring Committee, Centers for Disease Control Clinical Trials on the Treatment of Tuberculosis and Prevention of PCP, 1996 - Present.

Data and Safety Monitoring Board, NIAID (HPTN 039) Acyclovir for the Reduction of HIV Acquisition, 2002 - Present.

Data and Safety Monitoring Committee, NCI Polyp Prevention Study, 2005 - Present.

Data and Safety Monitoring Board, NIDDK Wisconsin Cystic Fibrosis Neonatal Screening Project, 2003 - Present.

Chair, Data and Safety Monitoring Board, NIH Center for Urban and African American Health, 2004- Present.

Data and Safety Monitoring Board, _____ Trial, 2003- Present.

Data and Safety Monitoring Board, _____, 2004-present.

Framingham Heart Study, Observational Study Monitoring Board, NIH, NHLBI, 2001 - Present.

Steering Committee, _____ Study, 2001 - Present.

Member, DSMB, _____, 2004-2005.

Chair, Data and Safety Monitoring Board, _____ Trial, 2001- 2004.

Chair, Data and Safety Monitoring Board, _____ Trial and
Combined Analysis of CV Events, 2003 - 2004.

Data and Safety Monitoring Board, _____ Medical Device Trial, 2002 - 2004.

Data Monitoring Committee, Veterans Administration Trial on Varicella Vaccine for the Prevention of Herpes
Zoster and its Complications, 1999 - 2004.

Steering Committee, _____ Study, 1999 - 2003.

NIH Gene Transfer Clinical Trials Design Working Group, 2004 - 2005.

Data Monitoring Committee, _____ in the Elderly, 1999 - 2002.

Data and Safety Monitoring Board, _____, 2000 - 2006.

Steering Committee, _____ Study, 1997 - 2000.

Data Monitoring Committee, _____,
1998 - 2001.

Data and Safety Monitoring Committee, _____ Outcomes Research
Study _____, 1999 - 2000.

HIVNET Prevention Research Review Group, NIAID, 1995 - 1998.

Data Monitoring and Safety Committee, NICHD Maternal-Fetal Medicine Units Network,
1991 - 1996.

Data and Safety Monitoring Board, NHLBI Dietary Approaches to Stop Hypertension (DASH) trial, 1994 -
1996.

Data and Safety Monitoring Committee, _____ Study, 1994 - 1996.

Data and Safety Monitoring Committee, Glaucoma Research Foundation Trial of Intraocular pressure reduction in
normal-tension glaucoma, 1996-1998.

Data and Safety Monitoring Committee, _____ Clinical Endpoint Protocol _____, 1995 - 1996.

Data Monitoring Board, NHLBI Prevention and Treatment of Hypertension Study, 1988 - 1994

Data and Safety Monitoring Committee, VA-NHLBI Trial of Reduction of Alcohol Intake in Lowering Blood
Pressure, 1989 - 1995

Data Monitoring Committee, NHLBI Sodium and Hypertension in Blacks, 1992 - 1995.

Data Monitoring Committee, NHLBI Women's Healthy Lifestyle Project, 1992 - 1995.

James D. Neaton

Data Monitoring Committee, NIDDK African American Study of Kidney Disease and Hypertension, 1992 - 1994

NIH Ad Hoc Data and Safety Monitoring Review Committee on Human Growth Hormone in Turner Syndrome, 1992 - 1993

Data Monitoring Committee, Children and Adolescent Blood Pressure Program, 1986-1990.

Special Review Committee, NCI National Bladder Cancer Project, Collaborative Group A, 1976 - 1982.

Policy Advisory Committee, NICHD Sudden Infant Death Syndrome Study, 1977 - 1984.

Participant, Keystone Dialogue (initiated by Vice-President Gore) on Establishment of Studies to Optimize Medical Management of HIV Infection, 1996.

NIH gp160 Trial Design Team, NIAID, 1992.

Member, Joint National Committee V on Detection, Evaluation and Treatment of High Blood Pressure (Subcommittee No. 1 on Definition, Prevalence, Evaluation, Screening and Goals of Therapy), 1992.

Consultant, Minnesota Department of Health, Impact of Vaccination on Haemophilus Disease Incidence, 1986 - 1992.

Consultant, Minnesota Department of Health, Smoking Cessation Protocol for Primary Care Physician Offices, 1987 - 1990.

Seminar Committee and Faculty Member, International Teaching Seminar on Cardiovascular Disease Epidemiology and Prevention, 1987 - 1994.

Scientific Program Committee, American Heart Association, 1984 - 1987.

Scientific Program Committee, 2nd Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, 1997.

Scientific Program Committee, XIth, XIIth, XIIIth, XIVth and XVth International Conferences on AIDS, 1996, 1998, 2000, 2002 and 2004.

Plus ad hoc committee assignments with NIH and consultations with the Food and Drug Administration and the pharmaceutical industry.

**APPEARS THIS WAY
ON ORIGINAL**

Publications, including Peer-Reviewed Papers, Letters, Commentaries, and Book Chapters:

1. Urokinase Pulmonary Embolism Trial Group. The Urokinase Pulmonary Embolism Trial. Circulation Vol. XLVII, No. 4 Supplement No. II., 1973.
2. Urokinase-Streptokinase Embolism Trial Group. Urokinase-Streptokinase Embolism Trial JAMA, Vol. 229. No. 2, 1974.
3. Multiple Risk Factor Intervention Trial Group. Design Considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J. Chronic Diseases, 30:261-275, 1977.
4. Multiple Risk Factor Intervention Trial Group. The MRFIT Behavior Pattern Study. Study Design, Procedures, and Reproducibility of Behavior Pattern Judgements. J. Chronic Diseases, 1978.
5. Kuller L, Neaton JD, Caggiula A, Falvo-Gerard L. Primary Prevention of Heart Attacks: The Multiple Risk Factor Intervention Trial. American Journal of Epidemiology, Vol. 112, No. 28, 1980.
6. Neaton JD, Broste S, Cohen L, Fishman E, Kjelsberg M. The Multiple Risk Factor Intervention Trial (MRFIT) VII. A Comparison of Risk Factor Changes Between the Two Study Groups. Prev Med 10:519-543, 1981.
7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: Risk Factor Changes and Mortality Results. JAMA, 248:1465-1477, 1982.
8. Kuller L, Hulley SB, Laporte R, Neaton JD, Dai W. Environmental Determinants, Liver Function and High Density Lipoprotein Cholesterol levels. Am. J. Epid., Vol. 117, No. 4, 1983.
9. Wentworth D, Neaton JD, Rasmussen W. An Evaluation of the Social Security Administration MBR File and the National Death Index in the Ascertainment of Vital Status. Am. J. Public Health, 73:1270-1274, 1983.
10. Neaton JD, Kuller L, Wentworth D., Borhani N. Total and Cardiovascular Mortality in Relation to Cigarette Smoking, Serum Cholesterol Concentration and Diastolic Blood Pressure Among Black and White Men Followed 5 Years. American Heart Journal, 108:759-770, 1984.
11. Multiple Risk Factor Intervention Trial Research Group. Exercise Electrocardiogram and Coronary Heart Disease Mortality in the Multiple Risk Factor Intervention Trial. Amer. J. Cardiology, 5:16-23, 1985.
12. Multiple Risk Factor Intervention Trial Research Group. Relationship Among Baseline Resting Electrocardiographic Abnormalities, Antihypertensive Treatment, and Mortality in the Multiple Risk Factor Intervention Trial. Amer. J. Cardiology, 5:1-15, 1985.
13. Grimm RH, Cohen JD, Smith W, Falvo-Gerard L, Neaton JD. Hypertension Management in the Multiple Risk Factor Intervention Trial (MRFIT): Six Year Intervention Results for Special Intervention and Usual Care Men. Archives of Internal Medicine, Vol. 145, July, 1985.
14. Grimm RH, Neaton JD, McDonald M, et al. Beneficial Effects from Systematic Dosage Reduction of the Diuretic Chlorthalidone: A Randomized Study Within a Clinical Trial. American Heart Journal, 109:858-864, 1985.
15. Grimm RH, Elmer PH, Neaton, JD, Segal MS, Prineas RJ. Role of Potassium Supplementation and Sodium Reduction in Controlling Blood Pressure in Hypertensive Men: Design and Methods of the Mt. Sinai Hypertension Trial. Edited by Paul K Whelton and Andrew Whelton, Marcel Dekker, Inc, New York, 1985.

16. Tillotson J, Neaton JD. Forms designed for implementation or evaluation of the MRFIT intervention process. In *Materials and Methods for a cardiovascular disease risk factor reduction program*. Edited by Jeanne Tillotson and SB Hulley. NIH Publication No. 85-1267, DHEW, March, 1985.
17. Grimm RH, Neaton JD, Ludwig B. The Prognostic Importance of Total White Blood Cell Count for All Cause, Cardiovascular and Cancer Mortality. *JAMA*, 254:1932-1937, 1985.
18. Cutler JA, Neaton JD, Hulley SB, Stamler J. Coronary Heart Disease and All Cause Mortality in the Multiple Risk Factor Intervention Trial: Overall and Subgroup Findings. *Preventive Medicine*, 14:293-311, 1985.
19. Shekelle RB, Hulley SB, Neaton JD, Billings J, Borhani N, et al. The MRFIT Behavior Pattern Study. II. Type A Behavior and Incidence of Coronary Heart Disease. *Amer. J. Epid.*, 122:559-570, 1985.
20. Kuller LH, Hulley SB, Cohen JD, Neaton JD. Unexpected Effects of Treating Hypertension in Men with ECG Abnormalities: A Review of the Evidence. *Circulation*, 73:114-123, 1986.
21. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. *Am. J. Med.*, 80:33-39, 1986.
22. Watkins LO, Neaton JD, Kuller, LH. Racial Differences in High-Density Lipoprotein Cholesterol and Coronary Heart Disease Incidence in the Usual Care Group of the Multiple Risk Factor Intervention Trial. *Am. J. Cardio.*, 57:538-545, 1986.
23. Rautaharju PM, Prineas RJ, Furburg CD, Neaton JD, Crow RS, Stamler J. The prognostic value of exercise ECG in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial (MRFIT) Experience. *J. Amer. College Cardio.*, 8:668-686, 1986.
24. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial (MRFIT): Coronary Death, Non-Fatal Myocardial Infarction, and Other Clinical Outcomes. *Amer. J. Cardio.*, 58:1-13, 1986.
25. Multiple Risk Factor Intervention Trial Research Group. Relationship Between Baseline Risk Coronary Heart Disease and Total Mortality in the Multiple Risk Factor Intervention Trial (MRFIT). *Prev. Med.*, 15:254-273, 1986.
26. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. *Amer. Heart J.*, Vol. 112, No. 4, 825-836, 1986.
27. Stamler J, Wentworth D, Neaton J. Is relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded? *JAMA*, Vol. 256, No. 20, 2823-2828, 1986.
28. Shekelle RB, Hulley SB, Neaton JD, et al. Type A behavior and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. In *Biological and Psychological Factors in Cardiovascular Disease*. Edited by T.H. Schmidt, T.M. Dembroski and G. Blumenchen, Springer-Verlag, Berlin 1986.
29. DuChene AG, Hultgren DH, Neaton JD, Grambsch PV, et al. Forms Control and Error Detection Procedures Used at the Coordinating Center of the Multiple Risk Factor Intervention Trial. *Controlled Clinical Trials (Suppl.)*, Vol. 7, No. 3, 345-455, 1986.
30. Neaton JD, Kannel WB, Wentworth D et al. Smoking plus hyper-cholesterolemia and coronary risk. Letter to the Editor. *Amer. Heart J.*, 1527-1528, 1987.

31. Grimm RH, Tillinghast L, Daniels K, Neaton JD, Mascioli S, Crow R, Pritzker M, Prineas R. Unrecognized myocardial infarction: Experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation, Vol. 75 (Suppl. II), II-6 - II-8, 1987.
32. MacMahon SW, Cutler JA, Neaton JD, et al. Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical and epidemiological studies. J. Hypertension, 4 (Suppl. 6), S14-S17, 1987.
33. Stamler J, Prineas RJ, Neaton JD, Grimm RH, et al. Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS). Am J. Cardiology, 59:512-602, 1987.
34. Grimm RH, Neaton JD, Prineas RJ. Primary prevention trials and the rationale for treating mild hypertension. Clinical Therapeutics, Vol. 9, Suppl. D, 20-30, 1987.
35. Cohen JD, Neaton JD, Prineas RJ, Daniels KA. Diuretics, serum potassium and ventricular arrhythmias in the Multiple Risk Factor Intervention Trial. Am. J. Cardiology, 60:548-554, 1987.
36. Rautaharju PM, Neaton JD. Electrocardiographic abnormalities and coronary heart disease mortality among hypertensive men in the Multiple Risk Factor Intervention Trial. Clinical and Investigative Med, 10:606-615, 1987.
37. Abdalla ISH, Prineas RJ, Neaton JD, et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men. Am. J. Cardiology, 60:1036-1042, 1987.
38. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation, 77:504-514, 1988.
39. Neaton JD, Grimm RH, Cutler JA. Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Cont Clinical Trials, 8:41S-53S, 1988.
40. Osterholm MT, Rambeck JH, White KE, Jacobs JL, Pierson LM, Neaton JD, Hedberg CW et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA, 260:1423-1428, 1988.
41. Shekelle RB, Hulley SB, Neaton JD, Borhani NO et al. Type A behavior (Letters to the Editor) Amer. Heart J., 115:1348-1350, 1988.
42. Gordon DJ, Probstfield JL, Garrison, RJ, Neaton JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79:8-15, 1989.
43. MacMahon S, Collins G, Rautaharju P, Cutler JW, Neaton, JD, Prineas R, Crow R, Stamler J. Electrocardiograph left ventricular hypertrophy and the effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am. J. Cardiology, 63:202-210, 1989.
44. Grimm RH, Kofran PM, Neaton JD et al. Effect of potassium supplementation combined with dietary sodium reduction on blood pressure in men taking antihypertensive medication. J. Hypertension, 6 (Suppl. 4), S591-S593, 1989.
45. Stamler J, Neaton JD, Wentworth, DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension, 13 (Suppl. I), 2-12, 1989.
46. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen J. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. NEJM, 320:904-910, 1989.
47. Grimm RH, Neaton JD, Elmer PJ, Svendsen KH, et al. The influence of potassium on blood pressure in hypertensive men on a low sodium diet: Results of a double-blind randomized trial. NEJM, 322:571-574, 1990.

48. Neaton JD, DuChene AG, Svendsen, KH, Wentworth D. An examination of the efficiency of some quality assurance methods commonly employed in clinical trials. Statistics in Medicine, 9:115-124, 1990.
49. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R et al. Blood pressure, stroke and coronary heart disease, Part I: Effects of prolonged differences in blood pressure - evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet, 335:765-774, 1990.
50. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypothesis of the trial. JAMA, 263:1795-1801, 1990.
51. Hung J, Huang T, Wu D, Yen M, Tsai S, Dahl H, Neaton JD, Dahl JC. The impact of dietary sodium, potassium and calcium on blood pressure. J. Formosan Med. Assoc., 89:17-22, 1990.
52. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation, 82:1616-1628, 1990.
53. Mascioli S, Grimm RH, Neaton JD, Stamler J, et al. The Treatment of Mild Hypertension Study (TOMHS): Characteristics of participants at baseline. Amer. J. Cardiol, 66:32C-35C, 1990.
54. Hanson LK, Grimm RH, Neaton JD. The relationship of white blood cell count to other cardiovascular risk factors. International J. of Epid., 19:881-888, 1990.
55. Mascioli S, Grimm RH, Launer C, Svendsen K, Flack J, Gonzalez N, Elmer P, Neaton JD. Sodium chloride raises blood pressure in normotensives: The Study of Sodium and Blood Pressure. Hypertension, 17:121-126, 1991.
56. Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study (TOMHS): A randomized, placebo controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Int. Med., 151:1413-1423, 1991.
57. Neaton JD, Bartsch G, Broste S, Cohen J, Simon N. A case of data alteration in the Multiple Risk Factor Intervention Trial. Controlled Clinical Trials, 12:761-740, 1991.
58. Ruth KE, Neaton JD. Evaluation of two biological markers of tobacco exposure. Preventive Medicine, 20:574-589, 1991.
59. Kuller L, Ockene J, Meilahn E, Wentworth D, Svendsen K, Neaton J. Cigarette smoking and mortality. Preventive Medicine, 20:638-654, 1991.
60. Shaten BJ, Kuller L, Neaton JD. Association between Baseline Risk Factors, Cigarette Smoking and CHD mortality after 10.5 years. Preventive Medicine, 20:655-669, 1991.
61. Stamler J, Neaton JD, Wentworth D, Shih J et al. Lifestyles and life-style related risk factors: their combined impact in producing epidemic cardiovascular disease and the potential for prevention (in "Multiple Risk Factors for Cardiovascular Disease," edited by A.M. Gotto, C. Lenfant, R. Paoletti and M. Some), Norwell; Kluwer, 19-25, 1992.
62. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. The white blood cell count and risk of lung cancer. Cancer, 69:681-684, 1992.
63. Davey-Smith G, Neaton JD, Ben-Shlomo Y, Shipley M, Wentworth D. Serum Cholesterol Concentration and Primary Brain Tumors: Amer. J. Epid. A Prospective Study, 135:259-265, 1992.

64. Neaton JD, Wentworth D. Influence of serum cholesterol, blood pressure, and cigarette smoking on death from coronary heart disease in 316,099 white men age 35-57 years: Overall findings and differences by age. Archives Int. Med., 152:56-64, 1992.
65. Neaton JD, Blackburn H, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Archives Int. Med., 152:1490-1500, 1992.
66. Pearce KA, Grimm RH, Rao S, Svendsen K, Liebson PR, Neaton JD. Population-derived comparisons of ambulatory and office blood pressures; implications for the determination of usual blood pressure and the concept of white coat hypertension. Archives Int. Med., 152:750-756, 1992.
67. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Amer. J. Epid., 136:59-70, 1992.
68. Davey Smith G, Phillips AN, Neaton JD. Smoking as "independent" risk factor for suicide: Illustration of an artifact from observational epidemiology? Lancet, 340:709-712, 1992.
69. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J et al. Report of the conference on low blood cholesterol: Mortality associations. Circulation, 86:1046-1060, 1992.
70. Stamler J, Stamler R, Neaton JD. National high blood pressure education program 20 years of achievement. Chapter 6: Blood pressure and cardiovascular risks: U.S. population data. NHLBI, 1992.
71. Neaton JD, Bartsch GE. Impact of measurement error and temporal variability on the estimation of event probabilities for risk factor intervention trials. Statistics in Medicine, 11: 1719-1729, 1992.
72. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Changes in serum creatinine in hypertensive participants in the Multiple Risk Factor Intervention Trial (MRFIT): Evidence that lowering blood pressure protects renal function in mild to moderate hypertensives. JAMA 268:3085-3091, 1992.
73. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. The relationship of apolipoprotein E phenotype to myocardial infarction and CHD mortality. Amer. J. Cardiology, 71:160-165, 1993.
74. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Coronary and cardiovascular mortality after an average of 12 years of follow-up in men screened for the Multiple Risk Factor Intervention Trial: Role of diabetes and other cardiovascular risk factors. Diabetes Care, 16:434-444, 1993.
75. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks; U.S. Population Data. Archives Int. Med., 153:598-615, 1993.
76. Stamler J, Dyer AR, Shekelle RB, Neaton JD, Stamler R. Relationship of baseline major risk factors to coronary and all cause mortality, and to longevity: Findings from long-term follow-up of Chicago cohorts. Cardiology, 82(2-3):191-222, 1993.
77. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease. Lessons from MRFIT and TOMHS. Amer. J. Kidney Diseases, 21 (Suppl):31-40, 1993.
78. Neaton JD, Grimm RH, Prineas RJ, Grandits G, et al for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study (TOMHS): Final Results JAMA, 270:713-724, 1993.

79. Stamler R, Stamler J, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted M, Leupker RV, Neaton JD, Steinberg D, Stone NJ, Van Horn L, Wissler RW. Serum Cholesterol: Doing the right thing. Circulation, 88:1954-1960, 1993.
80. Stamler R, Stamler J, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted M, Leupker RV, Neaton JD, Steinberg D, Stone NJ, Van Horn L, Wissler RW. Reply to Letters to the Editor on Editorial, "Serum Cholesterol: Doing the right thing". Circulation, 90:2573-2577, 1993.
81. Shaten BJ, Davey-Smith G, Kuller LH, Neaton JD. Risk factors for the development of Type 2 diabetes among men enrolled in the usual care group of Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care, 16:1331-1339, 1993.
82. Neaton JD, Wentworth DN, Kuller L. Risk factors for death from different types of strokes. Annals of Epidemiol., 3: 493-499, 1993.
83. Jacobson M, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Deyton L. Prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced HIV disease: Results of a randomized trial. J. Infectious Diseases, 169:384-394, 1994.
84. Lund EM, James KM, Neaton JD. Clinical trial design: veterinary perspectives. Journal of Veterinary Internal Medicine, 8:317-322, 1994.
85. Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Amer. J. Epidemiol, 139:166-172, 1994.
86. Abrams D, Goldman A, Launer C, Korvick J, Neaton JD, et al. A comparative trial of didanosine and zalcitabine in patients with human immunodeficiency virus infection who are intolerant or have failed zidovudine therapy NEJM, 330:657-662, 1994.
87. Stamler J, Neaton JD. Benefits of lower cholesterol Scientific American, Science and Medicine, 1:28-37, 1994.
88. Zhou SH, Rautaharju PM, Prineas RJ, Neaton JD, et al. Improved ECG models for estimation of LVH progression and regression incidence by redefinition of the criteria for a significant change in LVH status. J. Electrocard, 26:108-113, 1994.
89. Neaton JD, Wentworth DN, Rhame F, Hogan C, Deyton L. Considerations in choice of a clinical endpoint for AIDS clinical trials. Statistics in Medicine, 13:2107-2125, 1994.
90. Egger M, Neaton JD, Phillips AN, Davey-Smith G. Zidovudine and the risk of death: meta-analysis of randomized placebo controlled trials. Letter to the Editor. Lancet 343:1355, 1994.
91. Phillips AN, Sabin CA, Davey-Smith G, Egger M, Neaton JD. The European-Australian Collaborative Group Study 017 (letter to the Editor). AIDS 8:1185, 1994.
92. Sampson J, Neaton JD. On being poor with HIV (Commentary). Lancet 344:1100-1101, 1994.
93. Stamler J, Stamler R, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted DM, Luepker R, Neaton JD, et al. Doing the right thing: stop worrying about cholesterol (Letter to Editor) Circulation 90:2572-2577, 1994.
94. Prineas RJ, Grimm R, Grandits G, Liebson P, Neaton JD, Stamler J, et al. The effect of dietary sodium and body weight on echocardiographic measure of left ventricular mass among treated hypertensive men and women: four year change in the TOMHS Study. Nieren- und Hochdruckkrankheiten 23 (Suppl 1):S14-S21, 1994.

95. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. Chapter 9, In *Hypertension: Pathophysiology, Diagnosis, and Management*. Editors Laragh J, Brennen BM, Raven Press, New York, NY, 1995.
96. Liebson PR, Grandits G, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygiene therapy in the Treatment of Mild Hypertension Study (TOMHS). *Circulation* 91:698-706, 1995.
97. Chan I, Neaton JD, Saravolatz L, Crane L, Osterberger, J. Frequency of opportunistic events prior to death among HIV infected patients. *AIDS* 9:1145-1151, 1995.
98. Flack JM, Neaton JD, Grimm RH, Shih J, Cutler J, et al. Blood pressure and mortality among men with a history of myocardial infarction. *Circulation* 92:2437-2445, 1995.
99. Fleming TR, Neaton JD, Goldman A, DeMets DL, et al. Insights from monitoring the CPCRA didanosine/zalcitabine trial. *JAIDS* 10:(Suppl 2):S9-S18, 1995.
100. Elmer PJ, Grimm R, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, Neaton J. Lifestyle intervention results of the Treatment of Mild Hypertension Study (TOMHS) *Preventive Medicine* 24:378-388, 1995.
101. Neaton JD, Wentworth DN. Considerations in specifying the duration of followup of antiretroviral trials. *Medecine Biologie Environment* 23(2):171-179, 1995.
102. Klag MJ, Whelton PK, Randall BL, Neaton JD, et al. Blood pressure and incidence of end-stage renal disease in men. *NEJM* 334:13-18, 1996.
103. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of mortality from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial *Amer J Epid* 143:1002-1006, 1996.
104. Saravolatz L, Neaton JD, Sacks L, Deyton L, Rhame F, Sherer R. CD4+ cell count and patterns of mortality among patients infected with the human immunodeficiency virus enrolled in the Community Programs for Clinical Research in AIDS (CPCRA). *Clinical Inf Dis* 22:513-520, 1996.
105. Davey Smith G, Neaton JD, Wentworth DN, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: Part I - White men *Am. J. Pub. Health* 86:46-496, 1996.
106. Davey Smith G, Wentworth DN, Neaton JD, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: Part II - Black men *Am. J. Pub. Health* 86:497-504, 1996.
107. Grimm RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension: results of the Treatment of Mild Hypertension Study (TOMHS). *JAMA* 275:1549-1556, 1996.
108. Neaton J. How does one measure change in chronic disease? In *Encounters in Glaucoma Research 3. How to Ascertain Progression and Outcome*. Editors Anderson DR, Drance SM, Kugler Publications, New York, NY, 1996.
109. The Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection. The Keystone Center, July, 1996.

110. The MRFIT Research Group. Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial. Circulation 94:946-951, 1996.
111. Stamler J, Stamler R, Garside D, Greenlund K, Archer S, Neaton JD, Wentworth DN. Socioeconomic status, cardiovascular risk factors, and cardiovascular disease: findings on U.S. working populations. In: Report of the Conference on Socioeconomic Status and Cardiovascular Health and Disease, National Institutes of Health, National Heart, Lung, and Blood Institute, November, pp. 109-118, 1996.
112. Larntz K, Neaton JD, Wentworth DN, Yurik T. Data analysis issues for protocols with overlapping enrollment. Stat Med 15:2445-2453, 1996.
113. Burns DN, Hillman D, Neaton JD, Sherer R, et al. Cigarette smoking, bacterial pneumonia and other clinical outcomes in human immunodeficiency virus type 1 infection. JAIDS 13:374-383, 1996.
114. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA, 277:1293-1298, 1997.
115. El-Sadr W, Neaton JD. Wanted! A simple and meaningful HIV staging system. AJPH 87:546-548, 1997.
116. Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 79:2171-2177, 1997.
117. Neaton JD, Wentworth DN. Low serum cholesterol and risk of death from AIDS. AIDS 11:929-930, 1997.
118. Brancati F, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. End stage renal disease risk in diabetes mellitus: a prospective cohort study of 332,544 men screened for MRFIT. JAMA 278:2069-2074, 1997.
119. Torres RA, Neaton JD, Wentworth DN, Abrams D, Sherer R, Ward T, Sampson J. Acyclovir and survival among human immunodeficiency virus-infected patients with CD4 cell counts <500/mm³. Clin Inf Dis 26:85-90, 1998.
120. Neaton JD. Fundamentals of Clinical Trials (3rd edition). (Book Review). Cont Clinical Trials 19:50-52, 1998.
121. Davey Smith G, Neaton JD, Wentworth DN, Stamler R, Stamler J. Mortality differences between black and white men in the USA: the contribution of income and other factors among men screened for the MRFIT. Lancet 351:934-939, 1998.
122. Lund EM, James KM, Neaton JD. Veterinary randomized clinical trial reporting: a review of the literature. J Vet Internal Med 12:57-60, 1998.
123. Vaccaro O, Stamler J, Neaton JD. 16-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epid 27:636-641, 1998.
124. Stamler J, Greenland P, Neaton JD. The established major risk factors underlying epidemic coronary and cardiovascular disease. CVD Prevention 1:82-97, 1998.
125. Albert JM, Ioannidis JPA, Reichelderfer P, Conway B, Coombs RW, Crane L, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. Stat Med 17:2435-2462, 1998.
126. Black HR, Elliot WJ, Neaton JD, Grandits G, Grambsch P, et al. Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial Cont Clin Trials 19:370-390, 1998.
127. Capps L, Peng G, Doyle M, El-Sadr W, Neaton JD. Sexually transmitted infections in women with the human immunodeficiency virus Sexually Transmitted Diseases 25:443-447, 1998.

128. Connett J, Neaton JD. Response to: Clinical trials and treatment effects monitoring. Cont Clin Trials 19:525-526, 1998.
129. Green LA, Rhame F, Price RW, Capps L, Sampson J, Deyton L, Schnittman S, Fisher E, Perlman D, Bartsch GE, Krum E, Neaton JD. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS 12:1983-1990, 1998.
130. Vazquez JA, Sobel JD, Peng G, Schuman P, Steele-Moore L, Holloway W, Neaton J. Evolution of vaginal candida species recovered from HIV-infected women receiving fluconazole prophylaxis: the emergence of candida glabrata? Clin Inf Dis 28:1025-1031, 1999.
131. Prospective Studies Collaboration. Collaborative overview ('meta-analysis') of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. J Cardiovasc Risk 6:315-320, 1999.
132. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger G, Neaton J, Sharma D, Thiyagarajan B. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and population baseline characteristics of the Losartan Heart Failure Survival Study - ELITE II J Cardiac Failure 5:146-154, 1999.
133. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglius ML, Garside DB, Dyer AR, Liu K, Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282:2012-2018, 1999.
134. Eberly LE, Ohman PA, Neaton JD, Price RW, Abrams DI. Kaposi's Sarcoma and CNS Disease: a real association or an artifact of the control group? AIDS 14:995-1000, 2000.
135. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. A randomized study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F92, 2000.
136. Stamler J, Daviglius, Garside D, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol in three large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality, and to longevity. JAMA 284:311-318, 2000.
137. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm JA, Konstam MA, Riegeger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Study - ELITE II. Lancet 355:1582-1587, 2000.
138. Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. Antiviral Res 5:57-63, 2000.
139. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res and Human Retro 16:1123-1133, 2000.
140. Pitt B, Williams G, Remme W, Martinez, Lopez-Sendon, Maggioni A, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHEBUS Trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovas Drugs and Therapy 15:79-87, 2001.
141. Black HR, Elliott WJ, Neaton JD, Grandits G, et al. Baseline characteristics and early blood pressure control in the CONVINCe Trial. Hypertension 37:12-18, 2001.

142. Emery S, Lane HC, Neaton JD. Letter to the Editor. J Inf Dis 183:680, 2001.
143. Elliott WJ, Black HR, Neaton JD, Grandits G, Fakouhi D. The Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Chapter 21, In *Clinical Trials in Hypertension*. Editor: Black HR, Marcell Dekker, Inc. 2001.
144. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, Neaton JD. Evolution of antifungal susceptibility among *Candida* species recovered from HIV-infected women receiving fluconazole prophylaxis. Clin Inf Dis 33:1069-1075, 2001.
145. Jacob F, Polzin DJ, Osborne CA, Allen TA, Kirk C, Neaton JD, Lekcharoensuk C, Swanson LL. Clinical evaluation of dietary modification for treatment of spontaneous chronic renal failure in dogs. Amer Vet Med Assoc 220: 1163-1170, 2002.
146. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Duncan WR, Lane HC, Lundgren J, Neaton JD. Evaluation of subcutaneous Proleukin (interleukin-2) in a randomized international trial: rationale, design and methods of ESPRIT. Cont Clinical Trials 23:198-220, 2002.
147. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, et al. Both baseline drug resistance and antiretroviral drug levels are associated with short-term virologic responses to subsequent drug regimens. AIDS 16:1-8, 2002.
148. Domanski M, Pfeffer M, Neaton J, Norman J, et al. Pulse pressure and cardiovascular mortality: 16-year findings on 342,815 men screened for the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 287:2677-2683, 2002.
149. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.
150. Jacob F, Polzin DJ, Osborne CA, Neaton JD, Lekcharoensuk C, et al. Association between initial systolic blood pressure and risk of developing a uremic crisis or dying in dogs with chronic renal failure. J Amer Vet Med Assoc 222:322-329, 2003.
151. Eberly LE, Stamler J, Neaton JD. Relation of triglycerides, fasting and non-fasting, to coronary heart disease mortality. Archives of Internal Medicine 163:1077-1083, 2003.
152. Black HR, Elliott Wj, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 289:2073-2082, 2003.
153. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 348:1309-1321, 2003.
154. Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Annals Intern Med 138:680-681, 2003.
155. Greenland P, Knoll MD, Stamler J, Neaton JD, et al. Major risk factors are nearly universal antecedents of clinical coronary heart disease in three large U.S. cohorts. JAMA 290:891-897, 2003.
156. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Beginning to weigh the long term risks: incidence of grade 4 events, AIDS, and mortality in a large multicenter cohort receiving HAART. JAIDS 34:379-386, 2003.

157. Perez G, MacArthur RD, Walmsley S, Baxter J, Mullin C, Neaton JD. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clinical Trials 5:7-18, 2004.
158. Kuller LH, Thomas A, Grandits G, Neaton JD for the MRFIT Research Group. Elevated prostate-specific antigen (PSA) levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 13:373-377, 2004.
159. Eberly LE, Neaton JD, Thomas A, Dai Y. Multiple-stage screening and mortality for the Multiple Risk Factor Intervention Trial. Clinical Trials 1:148-161, 2004.
160. DeMets DL, Califf R, Dixon D, Fleming T, Ellenberg S, Freidman L, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, Snapinn S, Stump D, Temple R, Whitley R. Issues in regulatory guidelines for data monitoring committees. Clinical Trials 1:161-169, 2004.
161. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival - 25 year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Archives Int Med 164:1438-1443, 2004.
162. Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende M, Emery S, Fosdick L, Neaton JD, Tavel J, Davey R, Lane HC. CD4 cell response to three doses of subcutaneous interleukin-2: meta-analysis of three Vanguard studies. J Inf Dis 39:115-122, 2004.
163. Neaton JD. Quantitative Science. In: Mayer K, Pizer H (eds.). *The AIDS Pandemic. Impact on Science and Society*. Elsevier Academic Press, 2005.
164. Jacob F, Polzin DJ, Osborne CA, Neaton JD, Kirk CA, et al. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Amer Vet Med Assoc 226:393-400, 2005.
165. Davey Smith G, Shaten J, Svendsen K, Neaton JD, Haffner SM, Kuller LH. Incidence of type II diabetes in the randomized Multiple Risk Factor Intervention Trial. Annals Int Med 142:313-322, 2005.
166. Neaton JD, Kuller LH. Diuretics are color blind (editorial). JAMA 293:1663-1666, 2005.
167. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, et al. Results of the Controlled ONset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial by Geographical Region. J Hypertension 23:1099-1106, 2005.
168. Normand SLT, Rector TS, Neaton JD, Pina IL, Lazar R, et al. Clinical and analytic considerations in the study of health status in device trials for heart failure. J Card Fail 11:396-403, 2005.
169. Stamler J, Neaton JD, Garside DB, Daviglus ML. Current status: six established major risk factors – and low risk. In: Marmot MG, Elliott P (eds) *Coronary Heart Disease Epidemiology: From Aetiology to Public Health*, Oxford University Press, June 2005.
170. Thomas AJ, Eberly LE, Davey Smith G, Neaton JD, Stamler J. Race/ethnicity, income, major risk factors and CVD mortality AJPH 95:1417-1423, 2005.
171. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, et al. Comparison of losartan and captopril on heart failure - related outcomes and symptomatology from the Losartan Heart Failure Survival Study (ELITE II). Amer Heart J 150:123-131, 2005.

172. Zhao Y, Grambsch PM, Neaton JD. Comparison of numerical algorithms for bivariate sequential tests based on marginal criteria. Comp Stat and Data Anal 49:631-641, 2005.
173. Thomas AJ, Eberly LE, Neaton JD, Davey Smith G. Latino risk- and income-adjusted mortality in the men screened for the Multiple Risk Factor Intervention Trial (MRFIT) Amer J Epidemiol 162:569-578, 2005.
174. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD. CD4+ predicts clinical benefit in patients with advanced HIV with persistent viremia after one year of combination antiretroviral therapy. JID 192:1407-1411, 2005.
175. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in endpoint selection for heart failure trials: composite endpoints. J Card Fail 11:567-575, 2005.
176. MacArthur R, Perez G, Walmsley S, Baxter J, Mullin CM, Neaton JD. Comparison of CD4 cell count and HIV RNA level for short- and long-term risk of disease progression in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clinical Trials 6:127-135, 2005.
177. Neaton JD. Safeguards in studies: the role of data monitoring committees in clinical trials. Chance 18:55-58, 2005.
178. Neaton JD, Wentworth DN, Jacobson MA. Data monitoring experience in the TOXO Study (CPCRA 001). In: DeMets DL, Freidman L, Furberg C (eds.) Data Monitoring in Clinical Trials. A Case Studies Approach, Springer-Verlag, 2006.
179. Eberly LE, Prineas R, Cohen J, Vazquez G, Zhi X, Neaton JD, Kuller LW. Metabolic syndrome: risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial Diabetes Care 29:123-130, 2006.
180. Duran AS, Ivalo SA, Hakim A, Masciottra MF, Zlatkes R, Adissi L, Neaton JD, Losso M. Prevention of mother-to-child HIV transmission. Medicina (Buenos Aires) 66:24-30, 2006.
181. Ishani A, Grandits G, Grimm RH, Prineas RS, Neaton JD. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial J Amer Soc Nephrol 17:1444-1452, 2006.
182. Mocroft A, Neaton J, Bebachuk J, Staszewski S, Antunes A, Knysz B, Law M, Phillips AN, Lundgren J. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials 14:119-132, 2006.
183. Neaton JD, Mugglin AS. From observational studies to randomized trials: asking the right question at the right time. J Clin Periodontol 33:517-519, 2006.
184. Stamler J, Neaton J, Garside DB, Davigulus ML. The major adult cardiovascular diseases: a global historical perspective. In: Lauer R, Burns TL, Daniels S (eds.). Pediatric Prevention of Atherosclerotic Cardiovascular Disease. Oxford University Press, 2006.
185. Stamler J, Davigulus ML, Garside DB, Greenland P, Eberly LE, Yang L, Neaton JD. Low risk cardiovascular status: impact on cardiovascular mortality and longevity. In: Lauer R, Burns TL, Daniels S (eds.). Pediatric Prevention of Atherosclerotic Cardiovascular Disease. Oxford University Press, 2006.
186. Thomas A, Eberly L, Neaton JD, Davey-Smith G. ZIP-code based versus tract-based income measures as long-term risk-adjusted mortality predictors. Amer J Epid 164:586-590, 2006.
187. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with the metabolic syndrome. Atherosclerosis Sep 29 (epub) 2006.

188. Terry PD, Abramson JL, Neaton JD. Blood pressure and risk of death from external causes in men screened for MRFIT Amer J Epid DOI: 10.1093/aje/kwk014, 2006.
189. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count - guided interruption of antiretroviral treatment. NEJM 355:2283-2296, 2006.
190. Neaton JD, Normand SL, Gelijns A, et al. Designs for mechanical circulatory support device studies. J Card Fail 13:63-74, 2007.
191. The ESPRIT Research Group. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/ μ L who were assigned to 7.5 MIU interleukin-2. HIV Medicine 8:112-123, 2007.
192. Zhao Y, Grambsch PM, Neaton JD. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome (in press Clinical Trials).
193. Thomas AJ, Eberly LE, Neaton JD, Davey Smith G. Census-based and personally reported income measures as long-term risk-adjusted mortality predictors. (in press Public Health)
194. Neaton JD, Design of Outcome Trials, in Hypertension: A Companion Text to Braunwald's Heath Disease, Eds. Black HR, Elliott WJ, W.B. Saunders Co. (in press).
195. Adabag AS, Grandits G, Prineas RJ, Crow RS, Bloomfield HE, Neaton JD. Assessment of exercise heart rate parameters for predicting mortality and sudden death. (submitted to Circulation).
196. Greenberg B, Czerka B, Abraham WT, Neaton JD, et al. Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: Multi-center trial of the Orquis® Medical Cancion® System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). (submitted to J Card Fail).
197. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ count guided antiretroviral treatment interruption strategy in SMART: Role of CD4+ Counts and HIV-RNA levels during follow-up (submitted to Annals Int Med)

**APPEARS THIS WAY
ON ORIGINAL**

Presentations at Scientific Meetings, NIH/FDA Workshops and Scientific Symposia:

Design, implementation and field experience with the use of computer terminals in clinical centers in the Multiple Risk Factor Intervention Trial, Ninth International Biometric Society Conference, August, 1976, Boston, MA.

The "Oslo-like" cohort in the Multiple Risk Factor Intervention Trial. NHLBI Workshop on Primary Prevention of Coronary Heart Disease: Implications of the MRFIT. February, 1982, Bethesda, MD.

Total and CHD mortality in relation to smoking, serum cholesterol and diastolic blood pressure among Black and White men followed five years, AHA Cardiovascular Epidemiology Conference, March, 1983, San Diego, CA.

MRFIT subgroup findings, Sydenham Society, April 1983, Washington D.C. Do multiple risk factors explain racial differences and CHD mortality trends in Black populations? Symposium on recent Advances in Hypertension and Coronary Heart Disease in Black Populations, October, 1983, Baltimore, MD.

Use of logistic model in the design of intervention studies. Fifth Annual Meeting Society of Clinical Trials, May 1984, Miami, FL.

Monitoring of drug associated adverse reactions in a multiclinic trial. Eighty-ninth Annual Meeting of the American Society for Clinical Pharmacology and therapeutics, March, 1985, San Antonio, Texas.

Recruitment experience in the Multiple Risk Factor Intervention Trial. NIH Workshop on Recruitment of Patients in Cardiovascular Trials, April, 1986. Bethesda, MD.

Estimation of event rates for clinical trials, Spring Meetings of the Biometric Society (ENAR), March, 1988.

An examination of the efficiency of some quality assurance methods commonly employed in clinical trials, NIH Workshop on Cost and Efficiency in Clinical Trials, February, 1989.

Statistical design of the Treatment of Mild Hypertension Study (TOMHS). Tenth Annual Meeting Society of Clinical Trials, May, 1989, Minneapolis, MN.

What do you do when the data don't look right? Panel Discussion. Tenth Annual Meeting Society of Clinical Trials, May, 1989, Minneapolis, MN.

Facilitating critical evaluation of clinical trial reports. Annual Meeting. Council of Biology Editors, May 1989, Rochester, MN.

Comparison of 10 year coronary and cerebrovascular disease mortality rates by hypertensive status for black and white men screened in the MRFIT. American Heart Association, November 1989, New Orleans, Louisiana.

Quality control issues in multicenter clinical trials (Discussant), Society for Clinical Trials, May, 1990, Toronto, Canada.

Low serum cholesterol: risk of disease and determinants. NIH Workshop on Low Blood Cholesterol Levels and Disease, October, 1990, Bethesda, MD.

Lessons from Epidemiological Studies on the Prevention of Cardiovascular Disease, 5th Annual Meeting of Spanish Society of Preventive Cardiology, April, 1991, Jaca, Spain.

Long-term follow-up results of MRFIT, 5th Annual Meeting of Spanish Society of Preventive Cardiology, April, 1991, Jaca, Spain.

James D. Neaton

Issues in the design and conduct of AIDS trials. FDA Conference on the Role of Alternative Data Sources in AIDS Drug Development, May, 1991, Rockville, MD.

Ethnicity and renal disease: lessons from MRFIT and TOMHS. NIH Workshop on the Biology of Kidney Disease and Hypertension in Blacks, Washington D.C., December, 1991.

The challenges and opportunities of large, simple, community-based clinical trials: Four perspectives, organizer/chair of invited session, Biometric Society (ENAR), March, 1992, Cincinnati, Ohio.

Relative efficiency of taking research to the patient versus the patient to research, 13th Annual Meeting for Society for Clinical Trials, May, 1992, Philadelphia, PA.

Determinants of death from stroke. NIH Workshop on the Decline in Stroke Mortality, November 1992, Bethesda, MD.

Overview of toxoplasma prophylaxis studies. International Concensus Conference on Toxoplasma Prophylaxis, June, 1993, Berlin, Germany.

Is disease progression the optimal endpoint for AIDS Clinical Trials? IXth International Conference on AIDS, June 1993, Berlin, Germany.

Considerations in choice of a clinical endpoint for AIDS clinical trials. Societal Institute of the Mathematical Sciences 1993 AIDS Conference, June 1993, Blaubeuren, Germany.

What is going on at the lower end of the blood cholesterol distribution? 3rd International Conference on Preventive Cardiology, June 1993, Oslo, Norway.

Statistical design considerations for a large, simple trial (LST) on timing of combination nucleoside treatment, Joint Statistical Meetings, August, 1993, San Francisco, CA.

How to evaluate HIV/AIDS drugs. Japanese Health Foundation, March, 1994, Tokyo, Japan.

In search of the optimal endpoint for AIDS clinical trials. Journée d'Animation Scientifique. ANRS, April, 1994, Paris, France.

Considerations in specifying the duration of followup of antiretroviral trials. 2nd National Conference on Human Retroviruses and Related Infections, February, 1995, Washington,

Can it work? Does it work? Differing expectations for clinical trials. Arguments for pragmatic clinical trials for persons with HIV. American Association for the Advancement of Science, February, 1995, Atlanta, Georgia.

Relationship of serum cholesterol and blood pressure with risk of death from AIDS. American Epidemiological Society, March, 1995, Tampa, Florida.

How much on-site auditing of clinical trials should be performed? Chairperson, 16th Annual Meeting of the Society of Clinical Trials, May, 1995, Seattle, Washington.

How does one measure change in chronic disease? Encounters in Glaucoma Research, June, 1995, Vancouver, British Columbia.

James D. Neaton

- How should clinical endpoints be defined in antiretroviral trials? FDA, AIDS Task Force Workshop: Current Issues in AIDS Clinical Trials: Clinical Endpoint Confirmation Studies, September, 1995, Bethesda, Maryland.
- Considerations in specifying the duration of follow-up of antiretroviral trials. Overview and status of HIV: Conference on the Disease Prevention and Control, October, 1995, Pavia, Italy.
- Design issues for clinical endpoint trials: Cambridge Healthtech Institute's Second Annual Conference on Surrogate Markers of HIV, October, 1995, Tysons Corners, Virginia.
- Role of data and safety monitoring boards. American Academy of Neurology, April 1998, Minneapolis, Minnesota.
- Design and analysis issues for equivalence trials. 19th Annual Meeting, Society for Clinical Trials, May, 1998, Atlanta, Georgia.
- Making it work: Experience with a centralized biostatistics unit in an academic setting, Joint Statistical Meetings, August, 2000, Indianapolis, Indiana
- Challenges to clinical trial design in the setting of HAART (Invited State-of-the-Art Mini-lecture). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, 2000, Toronto, Ontario.
- Combined endpoints for HIV trials, NIH Endpoint Workshop, February, 2001, Bethesda, Maryland.
- Role of the sponsor in data management, steering committee, DSMB, stopping trials and publication, Fourth Cardiovascular Clinical Trials Workshop, December, 2001, Monte Carlo, Monaco.
- Practical issues in establishing and operating a data monitoring committee, Drug Information Association Workshop, January, 2002, Bethesda, Maryland.
- Predictors of cardiovascular disease: Implications for future HIV clinical trial design, 4th International Workshop on Adverse Drug Reactions and Lipodystrophy, September, 2002, San Diego, California.
- Issues in Data Monitoring Committees - Role of Independent Statistician, Duke Clinical Research Institute Symposia, January 2003, Washington D.C.
- Prevention of CVD events: 30 years of MRFIT, Festschrift Honoring Dr. Lewis H. Kuller, March 2003, Pittsburgh, PA..
- The collection and monitoring of drug safety data, Tools for Pre-Approval of Drug Safety Evaluation, FDA course, May 2003, Washington D.C.
- A new generation of clinical endpoint trials in HIV, 3rd Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, July 2003, London
- Case Study: CPCRA TOXO Study: Stopped twice, maybe three times. Clinical trial data monitoring committees. Policies, practices and controversies. Drug Information Association, September 2003, Washington D.C.
- Rationale, design, and implementation issues for large, long-term international trials in HIV. 6th Congreso Argentino de Sida, November 2003, Buenos Aires, Argentina.
- International Research in HIV/AIDS: Challenges and opportunities in the new millennium, Center for Public Health Education, February 2004, Minneapolis, Minnesota.

James D. Neaton

Composite endpoints. Key issues in endpoint selection and measurement for devices in heart failure. Heart Failure Society of America, April 2004, Washington D.C.

Socioeconomic status, ethnicity, risk factors & cardiovascular disease, Festschrift Honoring the Life and Achievements of Jeremiah Stamler, MD, October 2004, Chicago, Illinois.

Trials in AIDS: lessons for future MS trials? National Multiple Sclerosis Society, December 2004, Washington D.C.

Biostatistical issues in the design of type 1 diabetes trials (Co-chair of workshop), NIDDK, March 2005, Washington D.C.

Importance of follow-up in clinical trials, 2nd Annual PHIDISA Conference, August 2005, Capetown, South Africa.

Alternatives to randomized controlled trials for VAD development, HFSA/FDA Workshop, March 2006, Rockville, Maryland

Data Monitoring Board perspective on the Shingles Prevention Study, Society for Clinical Trials, May 2006, Orlando, Florida

Challenges in the design, implementation, and monitoring of HIV treatment trials, Statistical Society of Canada, May 2006, London, Ontario.

Results of the SMART study, HAART Oversight Committee, June 2006, Paris, France,

The dark side of composite endpoints, European Heart Failure Society, June 2006, Helsinki, Finland.

Randomized Clinical Trials: Designs for the future and obstacles to overcome. Current Issues in Clinical Research, Mayo Clinical Trials Services and the Academic Health Center, University of Minnesota, Minneapolis, MN, October 2006.

When to start HAART. Why an RCT can, and should, be performed. 11th International Workshop on HIV Observational Databases, Monte Carlo, March 2007.

Plus numerous departmental seminars at other institutions and at the University of Minnesota and abstracts.

**APPEARS THIS WAY
ON ORIGINAL**